Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | AURKA | O14965 | 1/20 | 0.48 |
| ▸ | PARP1 | P09874 | 6/20 | 0.47 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11162851 | 0.87 | GAA (0.55) | GAANPSR1AURKATRPA1MAPT | |
| SCHEMBL11151970 | 0.83 | ALOX5 (0.52) | GAANPSR1TRPA1MAPTSMN1; SMN2 | |
| SCHEMBL11149354 | 0.80 | NPSR1 (0.47) | GAANPSR1TRPA1MAPTMEN1 | |
| SCHEMBL4668382 | 0.78 | PARP1 (0.53) | AURKAPARP1TRPA1MAPTTP53 | |
| SCHEMBL9262051 | 0.75 | GAA (0.62) | GAANPSR1MAPTMEN1KMT2A | |
| SCHEMBL13098143 | 0.75 | GAA (0.62) | GAANPSR1MAPTMEN1KMT2A | |
| SCHEMBL30271059 | 0.73 | GAA (0.59) | GAANPSR1AURKAMAPTSMN1; SMN2 | |
| SCHEMBL3502571 | 0.72 | AURKA (0.59) | AURKAPARP1TRPA1HSD17B3 | |
| Hydrochloric Acid SCHEMBL30271128 | 0.72 | GAA (0.58) | GAANPSR1AURKAMAPTSMN1; SMN2 | |
| SCHEMBL13098115 | 0.72 | ALOX5 (0.55) | GAANPSR1TRPA1MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461145-B2 | Dibenzoazepine and dibenzooxazepine TRPA1 agonists | JANSSEN PHARMACEUTICA NV (BE) | 2013-06-11 | — | — | US | disclosed |
| US-8461145-B2 | Dibenzoazepine and dibenzooxazepine TRPA1 agonists | JANSSEN PHARMACEUTICA NV (BE) | 2013-06-11 | — | — | US | disclosed |
| US-20100273773-A1 | DIBENZOAZEPINE AND DIBENZOOXAZEPINE TRPA1 AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-28 | — | — | US | disclosed |
| US-20100273773-A1 | DIBENZOAZEPINE AND DIBENZOOXAZEPINE TRPA1 AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-28 | — | — | US | disclosed |
| WO-2009071631-A2 | DIBENZOAZEPINE AND DIBENZOOXAZEPINE TRPA1 AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273773-A1 | DIBENZOAZEPINE AND DIBENZOOXAZEPINE TRPA1 AGONISTS | TRPA1, TRPV1, TRPV2 | GAA 3708/4885NPSR1 386/4885AURKA 3990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.